Acute effect of whey peptides upon blood pressure of hypertensive rats, and relationship with their angiotensin-converting enzyme inhibitory activity

Molecular Nutrition and Food Research

Volumn 56, Issue 2, 2012, Pages 316-324

  Tavares, Tânia ^a   Sevilla, María Ángeles ^b   Montero, María José ^b   Carrón, Rosalía ^b   Malcata, F Xavier ^a,c  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY INSTITUTE OF MAIA   (Portugal)

Author keywords

Angiotensin converting enzyme; Antihypertensive effects; Bioactive peptides; Bradykinin; Spontaneously hypertensive rats; Whey proteins

Indexed keywords

ANGIOTENSIN I; ANTIHYPERTENSIVE AGENT; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; LACTALBUMIN; LACTOGLOBULIN; MILK PROTEIN; PEPTIDE; PEPTIDE FRAGMENT; WHEY PROTEIN;

ANIMAL; ARTICLE; BLOOD PRESSURE; CHEMISTRY; DRUG EFFECT; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; LACTALBUMIN; LACTOGLOBULINS; MALE; MILK PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED SHR;

CYNARA CARDUNCULUS; RATTUS;

EID: 84858310498     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201100381     Document Type: Article

References (54)

1. Chalmers, J., Blood pressure burden: vascular changes and cerebrovascular complications. J. Hypertens. 2000, 18, S1-S2.
2. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C. et al., The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J. Am. Med. Assoc. 2003, 289, 2560-2571.
3. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in Eastern Asia. Lancet 1998, 352, 1801-807.
4. Tsai, J. S., Chen, T. J., Pan, B. S., Gong, S. D. et al., Antihypertensive effect of bioactive peptides produced by protease-facilitated lactic acid fermentation of milk. Food Chem. 2008, 106, 552-558.
5. Murray, C. J. L., Lopez, A. D. (Eds.) The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020. Global Burden of Disease and Injury Series, vol. 1. Cambridge: Harvard School of Public Health 1996.
6. FitzGerald, R. J., Murray, B. A., Walsh, D. J., Hypotensive peptides from milk proteins. J. Nutr. 2004, 134, 980S-988S.
7. Leppälä, A. P., Bioactive peptides derived from bovine whey proteins: opioid and ACE-inhibitory peptides. Trends Food Sci. Technol. 2001, 11, 347-356.
8. Daemen, M. J., Lombardi, D. M., Bosman, F. T., Schwartz, S. M., Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res. 1991, 68, 450-456.
9. Geisterfer, A. A., Peach, M. J., Owens, G. K., Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 1988, 62, 749-756.
10. Geerlings, A., Villar, I. C., Zarco, F. H., Sánchez, M. et al., Identification and characterization of novel angiotensin-converting enzyme inhibitors obtained from goat milk. J. Dairy Sci. 2006, 89, 3326-3335.
11. Hong, F., Ming, L., Yi, S., Zhanxia, L. et al., The antihypertensive effect of peptides: a novel alternative to drugs? Peptides 2008, 29, 1062-1071.
12. Hartmann, R., Meisel, H., Food-derived peptides with biological activity: from research to food applications. Curr. Opin. Biotechnol. 2007, 18, 163-169.
13. Hernandez-Ledesma, B., Contreras, M. M., Recio, I., Antihypertensive peptides: production, bioavailability and incorporation into foods. Adv. Colloid Interface Sci. 2011, 165, 23-35.
14. Sánchez, D., Kassan, M., Contreras, M. M., Carrón, R. et al., Long-term intake of a milk casein hydrolysate attenuates the development of hypertension and involves cardiovascular benefits. Pharmacol. Res. 2011, 63, 398-404.
15. López-Fandiño, R., Otte, J., van Camp, J., Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. Int. Dairy J. 2006, 16, 1277-1293.
16. Miguel, M., Contreras, M. M., Recio, I., Aleixandre, A., ACE-inhibitory and antihypertensive properties of a bovine casein hydrolysate. Food Chem. 2009, 112, 211-214.
17. Quirós, A., Ramos, M., Muguerza, B., Delgado, M. A. et al., Identification of novel antihypertensive peptides in milk fermented with Enterococcus faecalis. Int. Dairy J. 2007, 17, 33-41.
18. Ijäs, H., Collin, M., Finckenberg, P., Pihlanto-Leppälä, A. et al., Antihypertensive opioid-like milk peptide α-lactorphin lacks effect on behavioural tests in mice. Int. Dairy J. 2004, 14, 201-205.
19. Jauhiainen, T., Korpela, R., Milk peptides and blood pressure. J. Nutr. 2007, 137, 825S-829S.
20. Nurminen, M. L., Sipola, M., Kaarto, H., Pihlanto-Leppälä, et al., α-Lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci. 2000, 66, 1535-1543.
21. Scholtz-Ahrens, K., Schrezenmeir, J., Effects of bioactive substances in milk on mineral and trace element metabolism with special reference to casein phosphopeptides. Braz. J. Nutr. 2000, 84, S147-S153.
22. Korhonen, H., Milk-derived bioactive peptides: from science to applications. J. Funct. Foods 2009, 1, 177-187.
23. Korhonen, H., Pihlanto, A., Food-derived bioactive peptides - opportunities for designing future foods. Curr. Pharm. Des. 2003, 9, 1297-1308.
24. Anderson, S., Renal effects of converting enzyme inhibitors in hypertension and diabetes. J. Cardiovasc. Pharmacol. 1990, 15, 11-15.
25. Jeunemaitre, X., Soubrier, F., Kotelevtsev, Y. V., Lifton, R. P. et al., Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71, 169-180.
26. Ondetti, M. A., Rubin, B., Cushman, D. W., Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977, 196, 441-444.
27. Phillips, M. I., Speakman, E. A., Kimura, B., Levels of angiotensin and molecular biology of the tissue renin-angiotensin systems. Regul. Pept. 1992, 43, 1-20.
28. Nelson, K. M., Yeager, B.F., What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction? Ann. Pharmacother. 1996, 30, 986-993.
29. Peach, M. J., Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 1977, 57, 313-370.
30. Timmermans, P. B. M. W. M., Wong, P. C., Chiu, A. T., Herblin, W. F. et al., Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 1993, 45, 205-251.
31. Kang, D. G., Kim, Y. C., Sohn, E. J., Lee, Y. M. et al., Hypotensive effect of butein via the inhibition of angiotensin-converting enzyme. Biol. Pharm. Bull. 2003, 26, 1345-1347.
32. Miguel, M., López, F., Ramos, M., Aleixandre, A., Short-term effect of egg-white hydrolysate products on the arterial blood pressure of hypertensive rats. Braz. J. Nutr. 2005, 94, 731-737.
33. Okamoto, K., Aoki, K., Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J. 1963, 27, 282-293.
34. Contreras, M. M., Carrón, R., Montero, M. J., Ramos, M. et al., Novel casein-derived peptides with antihypertensive activity. Int. Dairy J. 2009, 19, 566-573.
35. Fujita, H., Yokoyama, K., Yoshikawa, M., Classification and antihypertensive activity of angiotensin I-converting enzyme inhibitory peptides derived from food proteins. J. Food Sci. 2000, 65, 564-569.
36. Muguerza, B., Ramos, M., Sánchez, E., Manso, M. A. et al., Antihypertensive activity of milk fermented by Enterococcus faecalis strains isolated from raw milk. Int. Dairy J. 2006, 16, 61-69.
37. Nakamura, Y., Yamamoto, N., Sakai, K., Okubo, A. et al., Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J. Dairy Sci. 1995, 78, 777-783.
38. Nakamura, Y., Yamamoto, N., Sakai, K., Takano, T., Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J. Dairy Sci. 1995, 78, 1253-1257.
39. Miguel, M., Recio, I., Gómez-Ruiz, J. A., Ramos, et al., Angiotensin I-converting enzyme inhibitory activity of peptides derived from egg white proteins by enzymatic hydrolysis. J. Food Prot. 2004, 67, 1914-1920.
40. Barros, R. M., Malcata, F. X., Molecular characterization of peptides released from β-lactoglobulin and α-lactalbumin via cardosins A and B. J. Dairy Sci. 2006, 89, 483-494.
41. Tavares, T., Contreras, M. M., Amorim, M., Pintado, M. et al., Novel whey-derived peptides with inhibitory effect against angiotensin-converting enzyme: in vitro effect and stability to gastrointestinal enzymes. Peptides, 2011, 32, 1013-1019.
42. Fuglsang, A., Rattray, F., Nilsson, D., Nyborg, N., Lactic acid bacteria: inhibition of angiotensin converting enzyme in vitro and in vivo. Anton. Leeuwen. 2003, 83, 27-34.
43. Li, G. H., Le, G. W., Shi, Y. H., Shrestha, S., Angiotensin I-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. Nutr. Res. 2004, 24, 469-486.
44. Pripp, A. H., Sørensen, R., Stepaniak, L., Sørhaug, T., Relationship between proteolysis and angiotensin-I-converting enzyme inhibition in different cheeses. LWT - Food Sci. Technol. 2006, 36, 677-683.
45. Cheung, H. S., Wang, F. L., Ondetti, M. A., Sabo, E. H. et al., Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. J. Biol. Chem. 1980, 25, 401-407.
46. Gómez-Ruiz, J. A., Ramos, M., Recio, I., Angiotensin-converting enzyme-inhibitory activity of peptides isolated from Manchego cheese. Stability under simulated gastrointestinal digestion. Int. Dairy J. 2004, 14, 1075-1080.
47. Kim, S. K., Byun, H. G., Park, P. Y., Fereidoon, S., Angiotensin I converting enzyme inhibitory peptides purified from bovine skin gelatin hydrolysate. J. Agric. Food Chem. 2001, 49, 2992-2997.
48. Stevens, R. L., Micalizzi, E. R., Fessler, D. C., Pals, D. T., Angiotensin I converting enzyme of calf lung. Method of assay and partial purification. Biochem. 1972, 11, 2999-3007.
49. Adibi, S. A., Morse, E. L., Intestinal transport of dipeptides in man - relative importance of hydrolysis and intact absorption. J. Clin. Invest. 1971, 50, 2266-2275.
50. Hara, H., Funabiki, R., Iwata, M., Yamazaki, K., Portal absorption of small peptides in rats under unrestrained condition. J. Nutr. 1984, 114, 1122-1129.
51. Yamamoto, N., Maeno, M., Takano, T., Purification and characterization of an antihypertensive peptide from a yogurt-like product fermented by Lactobacillus helveticus CPN4. J. Dairy Sci. 1999, 82, 1388-1393.
52. Subissi, A., Evangelista, S., Giachetti, A., Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc. Drug Rev. 1999, 17, 115-133.
53. Campbell, D. J., Kladis, A., Duncan, A. M., Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994, 23, 439-449.
54. Bernstein, K. E., Shen, X. Z., Gonzalez-Villalobos, R. A., Billet, S., Okwan-Duodu, D., Ong, F. S., Fuchs, S., Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr. Opin. Pharm. 2011, 11, 105-111.